Competitive Analysis

The images below were part of an in-depth client presentation on the current competitive landscape, and the likely impact of ongoing trials that might affect the product’s future. The analysis was based on ongoing trials, expected data and anticipated positioning. Our analysis enabled our client to take steps as early as possible, to achieve more effective positioning of their product.

Product A	Study A initiates	Data from Study B presented at Association meeting		Study C to release interim results
Product B	New indication approval		Study R expected completed
Product C	Results from Study S	Study Y should be completed		Interim results of Study J
Product D	Study Z results to be presented at Association meeting	Results from Study F	Interim results of Study P	Study O initiates
Product E	Study V initiates	Data from Study N presented at Association meeting	Interim results of Study L	Study M expected completed

Product A	New indication for PCI (end of XXX?). Promote efficacy of XXX regimen in both UA/NSTEMI and STEMI patients undergoing PCI. Leverage data from XXX along with other data in STEMI including XXX and studies by XXX et al.
Product B	May be pushing to continue to capture patients eligible for early administration of eptifibatide. May position as optimal GP IIb/IIIa inhibitor to be used with early invasive strategy.
Product C	Continue efforts to expand use upstream in AMI patients planned for angioplasty.
Product D	Depending upon what XXX shows, focus may be on either replacing heparin or GP IIb/IIIa inhibitors in upstream management of UA/NSTEMI patients. Focus of strategy and indication will depend upon the results.
Product E	May leverage XXX to support role of high-dose clopidogrel in a new standard of care, however may still promote benefit of the high-dose without the need for the addition of a GP IIb/IIIa inhibitor.